1 Title page:

- 2 Full title: Impact of statin withdrawal on perceived and objective muscle function
- 3 Short title: Statin withdrawal and perceived and objective muscle function
- 4 Paul Peyrel^{1,2}, Pascale Mauriège^{1,2}, Jérôme Frenette^{3,4}, Nathalie Laflamme³, Karine
- 5 Greffard³, Sébastien S. Dufresne⁶, Claire Huth^{1,2}, Jean Bergeron^{3,5}, Denis R. Joanisse^{1,2,*}

- 7 ¹Department of Kinesiology, Université Laval, Québec, Québec, Canada
- 8 ²Research Center of the University Institute of Cardiology and Pulmonology of Quebec,
- 9 Québec, Québec, Canada
- 10 ³CHU de Québec Université Laval Research Center, Québec, Québec, Canada
- ⁴Department of Rehabilitation, Université Laval, Québec, Québec, Canada
- 12 ⁵Department of Laboratory Medicine and of Medicine, Université Laval, Québec, Québec,
- 13 Canada
- 14 ⁶Department of Health Sciences, Université du Québec à Chicoutimi, Saguenay, Québec,
- 15 Canada
- 16
- 17 * Corresponding author:
- 18 Email: denis.joanisse@kin.ulaval.ca (DRJ)

19 Abstract

Background and Aims: Statin-associated muscle symptoms (SAMS) are frequently
reported. Nevertheless, few data on objective measures of muscle function are available.
Recent data suggesting an important nocebo effect with statin use could confound such
effects. The objective was to assess if subjective and objective measures of muscle function
improve after drug withdrawal in SAMS reporters.

25 Methods: Patients (59 men, 33 women, 50.3±9.6 yrs.) in primary cardiovascular prevention

composed three cohorts: statin users with (SAMS, n=61) or without symptoms (No SAMS,

n=15), and controls (n=16). Force (FO), endurance (EN) and power (PO) of the leg
extensors (EXT) and flexors (FLE) and handgrip strength (FOHG) were measured using
isokinetic and handheld dynamometers, respectively. A 10-point visual analogue scale
(VAS) was used to self-assess SAMS intensity. Measures were taken before and after two
months of withdrawal.

Results: Following withdrawal, repeated-measures analyses show improvements for the
entire cohort in ENEXT, ENFLE, FOFLE, POEXT and POFLE (range +7.2 to +13.3%, all
p≤0.02). Post-hoc analyses show these changes to occur notably in SAMS (+8.8 to
+16.6%), concurrent with a decrease in subjective perception of effects in SAMS (VAS,
from 5.09 to 1.85). FOHG was also improved in SAMS (+4.0 to +6.2%) when compared
to No SAMS (-1.7 to -4.2%) (all p=0.02).

Conclusions: Whether suffering from "true" SAMS or nocebo, those who reported SAMS
had modest but relevant improvements in muscle function concurrent with a decrease in
subjective symptoms intensity after drug withdrawal. Greater attention by clinicians to
muscle function in frail statin users appears warranted.

42 1. Introduction

43 Among the pharmacological approaches used to treat hypercholesterolemia, statins are considered the reference lipid-lowering drugs (1). By significantly reducing cholesterol 44 45 synthesis through HMG-CoA reductase inhibition, they are commonly used as part of 46 primary or secondary prevention to limit the risk of cardiovascular disease (CVD). Statins 47 are now used by over 200 million people around the world (2), but controversies remain on the nature and prevalence of their side effects. These effects can include the 48 development of diabetes, elevated circulating liver enzymes and joint pain (3, 4), but statin-49 50 associated muscle symptoms (SAMS) are the most frequently reported side effects of statin 51 use. Mild myalgia has often been reported by 5-10% of statin users (4, 5), this rate reaching 52 around 20% in a few reports (6, 7).

53 That statin use could lead to a variety of mild or moderate muscle symptoms is not surprising. Indeed, myopathies and rhabdomyolysis have been documented from statin use 54 55 (8-10), giving credence to the idea that less severe symptoms are possible or even likely. 56 Nevertheless, recent work has called into question the true prevalence of SAMS, as 57 distinguishing between the harmful effects truly associated with statins and the so-called 58 nocebo effect is not trivial (11-14). It is thus essential to develop strategies in order to 59 identify the "true" statin-intolerant patients (15). Among those proposed is the recent 60 "SAMS - Clinical Index" (SAMS-CI) (16) which purports to classify the origin of muscle 61 pain according to whether it is "unlikely", "possibly" or "probably" related to statin use. 62 This tool remains to be validated for use in a broad patient population.

63 While statins promote an increase in reported muscle complaints, in different muscle64 groups (especially pectorals, quadriceps, biceps, and deltoids) (17), they do not appear to

65 lead to a systematic decrease in strength or endurance, physical activity level or 66 performance (18-23). A recent study by Kawai et al. (2018) (24) assessed the physical 67 performances of 1.022 adults aged between 65 and 88 vrs., depending on whether the 68 participants were using statins or not. In this study, significantly lower handgrip strength (respectively 26.1 ± 7.4 kg and 28.1 ± 8.5 kg, mean \pm standard deviation [SD]) and normal 69 70 walking speed (respectively 1.30 ± 0.24 m/s and 1.36 ± 0.26 m/s) were observed between 71 statin users compared with non-users. However, when these data were adjusted for SAMS 72 risk factors (age, sex, body mass index [BMI], and number of medications), differences 73 were lost, suggesting that SAMS were contributory to these effects.

74 The current state of the scientific literature is both limited and contradictory. Some 75 studies suggest that SAMS have no impact on muscle performance (25, 26). However, as illustrated by Parker et al. (2013), a reduction in performance has been previously 76 77 demonstrated in patients reporting SAMS in some observational studies (22). Nevertheless, 78 in the work of Parker et al. (2013), while a decrease in 5 of the 14 performance variables 79 studied did occur in statin patients reporting SAMS (n=18), 4 performance variables also 80 deteriorated in patients reporting muscle symptoms in the placebo group (n=10). In general, 81 the probability that studies examining the muscle function effects of statins include both true SAMS-sufferers and nocebo reporters certainly is a limiting factor in the current 82 83 understanding of this phenomenon.

The present study therefore aimed first to focus on the effects of statin withdrawal on perceived SAMS and objective muscle performance, and second to explore the impact of this manipulation according to the SAMS-CI category.

87 2. Methods

88 2.1 Participants

Caucasian men (n=59) and women (n=33) aged 30 to 60 years (50.3 ± 9.6 yrs. [mean \pm 89 90 SD]) and affiliated to the cardiovascular (CV) lipid prevention clinic at the CHU de 91 Québec-Université Laval (CHUL) were enrolled. These were patients treated with statins 92 in primary CV prevention and with normal blood creatine kinase (CK) levels. Two statin 93 groups were formed: a first self-reporting SAMS (SAMS, n=61) and a second without SAMS (No SAMS, n=15). A third group of participants not taking statins served as controls 94 95 (Controls, n=16). In this work, data are pooled from a pilot study and a main study (Fig 1). 96 In both studies, the inclusion and exclusion criteria and procedures, with a few exceptions 97 mentioned below, were the same. Participants had to be in good general health, sedentary 98 or moderately active (i.e., less than one hour of leisure-time physical activity performed 99 per week) and to present no contraindications for physical function testing. Patients were required to have a low or moderate Framingham risk score, which allowed the research 100 101 team to modify their lipid-lowering regimen for the study period. Finally, patients who 102 were previously prescribed other statins or doses prior to their current regimen were not 103 excluded. However, self-reported SAMS needed to be temporally associated with statin 104 use and be present with the current prescription.

Participants were excluded from the study if they had taken other lipid-lowering drugs
or any natural treatment that affects lipid metabolism in the last year. Other exclusion
criteria included vitamin D deficiency (calcifediol (25(OH)D₃) levels below 12.5nmol/L)
or vitamin D supplementation; elevated circulating CK levels (>170u/L for women;
>195u/L for men) or a history of elevated CK of known or unknown etiology; hepatic or

110 renal failure; untreated hypo- or hyperthyroid; any treatment promoting an increased risk 111 of myopathy; any infection requiring the use of an antibiotic; a daily consumption of more 112 than 60mL of grapefruit juice; hereditary muscle disorders or myopathy, polymyositis or 113 inflammatory myopathy; use of corticosteroids; comorbidities leading to muscle or bone 114 pain (fibromyalgia, arthritis, sensory or intrinsic neuropathy, spinal disease, loss of 115 reflexes, atrophy muscle group); unexplained cramps; cancer in the five years prior to 116 entry into the study; diabetes, stroke, or any known sickle cell trait. In addition, pregnancy, 117 breastfeeding, a physical disability or previous injury interfering with stress testing, 118 depression (within the past three years) or treatment with antidepressants, the use of 119 antipsychotic drugs and alcohol abuse were also exclusion factors.

In a subset of participants (n=22) for which data were available, comparisons based on
 SAMS-CI category were performed for SAMS-reporting participants (16).

The protocol was approved by the CHU de Québec – Université Laval ethics committee, and all participants provided informed written consent. The study design complied with the principles of the Declaration of Helsinki and was registered in clinicaltrials.gov (NCT01493648). Recruitment and data acquisition were conducted from October 2011 to October 2015.

127

128

<insert Fig 1 here>

129 Fig 1. Diagram of patients' recruitment

130 M: men; SAMS: statin-associated muscle symptoms; W: women.

131

132 2.2 Procedures

Participants first participated in an inclusion visit. Height (stadiometer), body mass (calibrated scale), BMI (kg/m²), and waist circumference (WC) were assessed (weight, BMI, and WC were not measured after statin withdrawal in the pilot study). Participants completed a standardized recruitment questionnaire, based on current statin type and dosage, statins use history, predisposing conditions or factors that could contribute to muscle problems, as well as an assessment of eating habits.

The experimental protocol consisted of two months of statin withdrawal with pre- and post-withdrawal assessments of subjective and objective measures of muscle function and blood levels of several markers of interest. Data were collected by a blinded experimenter. On the day of pre-test, participants were instructed to take their usual dose of statin at their habitual time. The two-month interval was based on previous studies that showed most SAMS appeared or were resolved within this period of the introduction or withdrawal of the medication (5, 27).

146

147 2.3 Measurements

148 *2.3.1 Self-reported muscle symptoms*

Participants self-reported the presence of SAMS by describing what symptom(s) they believed to be the result of medication use. These symptoms typically included myalgia, stiffness, weakness, fatigue and/or cramps. They were then asked to rate the intensity of the symptom(s) they reported by answering the following question (translated from French) on a visual analog scale (VAS):

On a scale of 0 to 10 (10 being the most intense or unbearable), rate the current intensity
of the symptom(s) which you believe to be related to statin use

156

157 *2.3.2 Blood tests*

158 A venipuncture was performed following a 12-h overnight fast and prior to muscle 159 function tests. The levels of a number of circulating factors were assessed from these 160 samples (Table 1 and S1 Table), including markers of muscle (CK and myoglobin [MB]) 161 and liver (alanine aminotransferase [ALT] and aspartate aminotransferase [AST]) damage, 162 the plasma lipid-lipoprotein profile (total cholesterol [TC]; triglycerides [TG]; high density 163 lipoprotein [HDL]; low-density lipoprotein [LDL]; TC/HDL; apolipoprotein B-100 164 [APOB-100] and apolipoprotein A1 [APOA1]), and 25(OH)D₃. Only ALT, AST and CK 165 were assessed in the pilot study. All were measured using standardized clinical assays at 166 the CHU de Québec – Université Laval clinical laboratory.

167

168 *2.3.3 Muscle performance*

Muscle performance was assessed using a Biodex isokinetic dynamometer (Biodex Medical Systems, Shirley, NY). The system has shown good reproducibility in the healthy population (28). Patients were seated in an upright position and the resistance pads were aligned according to the manufacturer's instructions. The maximum force (FO), power (PO) and endurance (END) of the extensor (EXT) and flexor (FLE) muscles of the dominant leg were measured.

Testing began with a warm-up consisting of five repetitions at 60°/s including one movement at maximum voluntary contraction (MVC). Subsequently, the maximum force (Nm) was measured during three MVCs each at 60°/s and 180°/s. The highest measured value was retained. Endurance and power were measured over 15 MVC repetitions at

179 180°/s. Endurance was calculated as the total (sum) of strength developed during all 15 180 repetitions (Nm). Power was calculated (W) by multiplying the endurance value with the 181 total time required for the patient to complete the repetitions; then divided by the number 182 of repetitions (n=15). For all tests, each maximum contraction was performed within the 183 first 90 degrees of the knee's range of motion.

184

185 *2.3.4 Handgrip strength*

Handgrip strength was measured with a Jamar hydraulic hand dynamometer (Asimov 186 187 Engineering, Los Angeles, CA). This tool is reliable and validated (29). Patients performed 188 the test seated with their feet slightly apart, the unassessed arm at their side, the arm 189 assessed at 90° and not resting on an armrest. The handle of the dynamometer was adjusted so that the handle rested on the middle of the four fingers while positioning the base of the 190 191 dynamometer on the first metacarpal. Once in position, the patient was asked to squeeze 192 the handle of the dynamometer as hard as possible for 3s while exhaling. One min of rest 193 between each contraction was respected. The best of the three repetitions was retained to 194 assess handgrip force (kg) in the right (FOHGR) and left (FOHGL) hands In the pilot study, 195 handgrip strength was only measured in the dominant hand.

196

197 2.4 Statistical analyses

Data are expressed as mean \pm SD. Sample size calculations were performed using predicted changes to measures of physical performance following statin withdrawal. Using a one-tailed model with p=0.01 and a power of 80% and aiming for a 20% average increase

in several muscle function tests using observed standard deviations (SD) from preliminarydata from 9 participants, required total n values were found to range from 15 to 30.

203 All statistical analyses were performed using JMP software (SAS Institute, Cary, NC). 204 In cases of missing data for any given measure, participants were removed from that 205 analysis. Between group differences for variables not measured repeatedly over time were 206 analyzed by ANOVA followed by Tukey post-hoc tests. A repeated measures factorial 207 design was used to assess differences between groups and over time using the "Full 208 factorial mixed design" add-in for JMP (30), and post-hoc analyses performed using Tukey 209 tests. Chi-square tests were used to assess distribution differences across groups from 210 contingency tables. These latter tests were not performed when expected observations in a 211 cell fell below n=5. All results were considered statistically significant when p reached 212 <0.05. Finally, Cohen's d values for pairwise comparisons were used to assess effect sizes 213 (ES) for within-group changes over time and to qualify changes as trivial (Cohen's d < 0.2), 214 small (0.2-0.5), moderate (0.5-0.8), or large (>0.8).

3. Results

216 *3.1. Anthropometric and metabolic variables at baseline*

217 Participants' characteristics are shown in Table 1. Whereas the SAMS group was 218 significantly older on average (+10.6 yrs.) than the Control group, the No SAMS group 219 was intermediate (5.4 yrs. younger than SAMS) but not significantly different from the 220 other two groups. Overall, the SAMS group presented a slightly more deteriorated health 221 profile, as revealed by higher BMI (+4.1kg/m²) compared to the No SAMS group. 222 Increased adiposity in the SAMS group was also indicated by a greater WC, on average 223 +11.2 cm more than that of the No SAMS and Control groups (p=0.01). Despite a 224 significantly higher ALT level in the SAMS group compared to other groups, all markers 225 of muscle and liver injuries (CK, MB, AST, and ALT) were below values of clinical 226 concern. Finally, 25(OH)D₃ values did not differ between groups and were not indicative 227 of vitamin D deficiency.

	S A	MS		No S	AMS		Contr	ols			ANOVA	
	SA	WI3		110 5	AMS		Conti	015		Time	Category	T*C
-	Pre	Post	ES	Pre	Post	ES	Pre	Post	ES	- р	р	р
Men/Women, n	38	/23		10)/5		11/	5		-	0.87\$	
Age (years)	53.0 ± 8.4^{a}	-	-	47.6 ± 9.6^{ab}	-	-	42.4 ± 9.4^{b}	-	-	-	<0.01	-
Anthropometric char	acteristics											
n	37 t	o 59		14 t	o 15		14 to	15				
Height (cm)	166 ± 13^{a}	-	-	172 ± 8^{a}	-	-	169 ± 8^{a}	-	-	-	0.20	-
Weight (kg)	80.9 ± 14.7	80.8 ± 14.7	0.00	74.0 ± 12.3	73.9 ± 12.0	-0.01	74.8 ± 13.3	$74.8~\pm~13.9$	-0.01	0.76	0.10	0.97
BMI (kg/m ²)	29.2 ± 4.5	29.0 ± 4.5	-0.06	25.1 ± 3.2	25.1 ± 3.2	0.00	26.9 ± 5.9	$26.9~\pm~5.9$	0.00	0.56	0.01	0.66
WC (cm)	95.4 ± 17.2	93.9 ± 10.1	-0.07	86.2 ± 11.1	86.4 ± 11.5	0.01	84.3 ± 13.0	85.1 ± 13.8	0.05	0.93	<0.01	0.77
Plasma metabolic var	iables											
n	41 t	o 60		1	4		15					
$MB (\mu g/L)$	29.9 ± 11.0	28.5 ± 9.3	-0.13	29.5 ± 10.7	27.9 ± 11.9	-0.18	33.7 ± 18.1	$30.8~\pm~10.4$	-0.08	0.13	0.46	0.84
CK (U/L)	130 ± 76	126 ± 90	-0.11	132 ± 62	118 ± 46	-0.17	163 ± 112	162 ± 88	0.06	0.19	0.25	0.65
ALT (U/L)	30.0 ± 17.6	$26.9 \pm 15.6^*$	-0.22	23.6 ± 12.0	19.1 ± 8.2	-0.30	18.6 ± 5.5	18.4 ± 6.3	-0.04	<0.01	0.02	0.20
AST (U/L)	22.5 ± 5.9	21.7 ± 6.4	-0.17	22.0 ± 6.3	20.6 ± 5.3	-0.20	19.7 ± 5.1	18.5 ± 4.2	-0.15	0.04	0.15	0.92
TC (mmol/L)	4.81 ± 0.98	$6.78 \pm 1.34^*$	1.73	4.60 ± 0.84	$6.85 \pm 1.37^*$	1.92	5.06 ± 0.83	5.21 ± 0.93	0.16	<0.01	0.04	<0.01
TG (mmol/L)	1.89 ± 1.22	2.19 ± 1.20	0.31	1.08 ± 0.54	1.66 ± 0.90	0.70	1.15 ± 1.05	1.20 ± 1.07	0.03	<0.01	<0.01	0.22
HDL (mmol/L)	1.31 ± 0.37	1.31 ± 0.35	-0.01	1.55 ± 0.42	1.49 ± 0.44	-0.16	1.56 ± 0.41	1.63 ± 0.42	0.16	0.93	0.03	0.08
LDL (mmol/L)	2.71 ± 0.97	$4.59 \pm 1.31^*$	1.86	2.56 ± 0.71	$4.61 \pm 1,26^*$	2.02	3.11 ± 0.92	3.18 ± 1.03	0.04	<0.01	0.26	<0.01
TC/HDL (mmol/L)	3.95 ± 1.36	$5.54 \pm 1.80^*$	1.10	3.09 ± 0.64	$4.82 \pm 1.07^*$	1.85	3.48 ± 1.26	3.45 ± 1.33	-0.04	<0.01	<0.01	<0.01
APOB-100 (g/L)	0.93 ± 0.26	$1.41 \pm 0.33^*$	1.69	0.87 ± 0.17	$1.36 \pm 0.28^*$	2.13	0.91 ± 0.22	0.93 ± 0.28	0.05	<0.01	<0.01	<0.01
APOA1 (g/L)	1.47 ± 0.22	1.44 ± 0.24	-0.11	1.56 ± 0.24	1.54 ± 0.25	-0.09	1.61 ± 0.23	1.60 ± 0.20	0.00	0.36	0.09	0.81
25(OH)D ₃ (mmol/L)	74.2 ± 32.5	$68.4 \pm 32.0^{\dagger}$	-0.18	71.2 ± 27.0	63.8 ± 25.0	-0.25	66.9 ± 18.7	68.3 ± 19.2	0.06	0.02	0.91	0.12
Self-reported muscle symptoms intensity												
n	6	0		1	4		15					
VAS (0 to 10)	5.09 ± 1.81	$1.85 \pm 2.25^*$	-1.22	$0.00~\pm~0.00$	$0.00~\pm~0.00$	/	$0.00~\pm~0.00$	$0.00~\pm~0.00$	/	<0.01	<0.01	<0.01

Table 1. Pre- and post-statin withdrawal anthropometric characteristics and metabolic variables

230 Data are expressed as mean \pm standard deviation; \$ P-value is shown here by a chi-squared test; Post value with * is statistically different

from the pre value with $p \le 0.01$; Post value with \dagger is statistically different from the pre value with $p \le 0.05$. ALT: alanine aminotransferase;

- APOA1: apolipoprotein A1; APOB-100: apolipoprotein B-100; AST: aspartate aminotransferase; BMI: body mass index; WC: waist
- 233 circumference; CK: creatin kinase; ES: effects size; HDL: high-density lipoprotein; LDL: low-density lipoprotein; MB: myoglobin;
- 234 SAMS: statin-associated muscle symptoms; TC: total cholesterol; TC/HDL: cholesterol total / HDL cholesterol; TG: triglycerides; VAS:
- visual analogic scale; 25(OH)D₃: Calcifediol.

236

237

3.2. Clinical aspects of statin users

Most statin users in this study were prescribed rosuvastatin (50% of participants) or atorvastatin (35.5%). This distribution was expected given the usual clinical practice at the CHU de Québec – Université Laval lipid clinic. A detailed breakdown of the clinical profile of participants in this study is presented in S2 Table.

242 The Framingham Score revealed that the CV risk over ten years was low (<10%) for all patients (except for 1 patient [13%, moderate risk]). Nevertheless, the CV risk for the 243 244 SAMS group was on average 1.43% and 1.96% higher than that of the No SAMS and 245 Control groups, respectively. Most participants in the SAMS and No SAMS groups had 246 been using stating for 12 to 48 months (80.4% and 100% respectively). Nineteen 247 participants indicated having previously not tolerated some forms of statins, their 248 distribution being roughly equal in SAMS and No SAMS groups (respectively 31.9% and 249 26.7% of participants). Among the 38 participants with a family history (first degree) of 250 CVD, 35 were present in groups treated with statins. 91.3% of participants with a family 251 history (first degree) in terms of lipid-lowering treatment were present in these same statin-252 taking groups. Finally, of the 30 participants in the SAMS group who reported a family 253 history (first degree) of lipid-lowering therapy, 6 also reported a self-reported family 254 history of SAMS.

255

256

3.3. Statin withdrawal effects on anthropometry and metabolic variables

No changes to anthropometric measures were observed following statin withdrawal ineither the SAMS or No SAMS groups (Table 1).

259 In addition, and as expected, a significant deterioration of the lipid-lipoprotein profile 260 was seen in all statin users following drug withdrawal. Indeed, repeated-measures ANOVA 261 analyses revealed several time, category, and time x category interactions for most lipids 262 (Table 1). In brief, while no change was observed in any lipid levels studied in the control group in the same period, both SAMS and No SAMS statin users experienced a deteriorated 263 lipid-lipoprotein profile, reflected by increased TC, TG, LDL, TC/HDL, and APOB-100 264 265 levels following medication withdrawal. HDL and APOA1 levels remained, however, 266 unchanged.

With respect to markers of tissue damage or dysfunction, while ALT and AST levels are somewhat reduced following withdrawal of the drug, these values always remained well below clinical thresholds. The muscle damage specific markers MB and CK did not differ across groups or change following statin withdrawal and remained well below clinical values of clinical concern throughout the study (Table 1).

Finally, despite a small decrease in 25(OH)D₃ levels in the statin groups, these values remained not different from those of the control group and were not indicative of vitamin D deficiency. The baseline levels and impact of statin withdrawal on several other plasma variables are presented in S1 Table.

276

277 *3.4. Perceived muscle effects and objective physical performance*

As depicted in Table 1, a significant improvement in the perception of muscle symptoms following statin withdrawal was observed in the SAMS group, decreasing by 3.24 units on the 10-point scale.

281 Results related to objective physical performance showed significant time effects for 282 all Biodex isokinetic dynamometer measures: ENEXT (+8.17% overall for the entire group 283 [ES: 0.22, small effect]), ENFLE (+11.6% [ES: 0.30, small effect]), FOFLE (+7.20% [ES: 284 0.22, small effect]), POEXT (+9.04% [ES: 0.24, small effect]) and POFLE (+13.3% [ES: 285 0.34, small effect]), except for FOEXT (+3.24%, NS, [ES: 0.11, trivial effect]) (Fig 2). 286 However, few between group differences were seen at baseline, with only ENFLE and 287 POFLE being slightly lower in the SAMS group. Although there was no time x category 288 interaction for any of these measures, post-hoc analyses revealed statistically significant 289 within-group improvements only in the SAMS group following statin withdrawal, and this 290 was true for five of the six isokinetic dynamometer measures (improvement range +8.8 to 291 16.6%, [ES: 0.25 to 0.39, all small effects]).

292 In terms of handgrip performance, although neither left (FOHGL) nor right (FOHGR) 293 force showed any time or category effects, a significant interaction was observed for 294 FOHGL, and this reached near statistical significance (p=0.06) for FOHGR. In both cases, 295 the greatest increase in force following statin withdrawal was seen in the SAMS group 296 (+4.0% for FOHGR [ES: 0.09, trivial effect]; +6.2% for FOHGL, [ES: 0.18, trivial effect]), 297 while values decreased in the No SAMS group (-4.2% for FOHGR [ES: -0.16, trivial 298 effect]; -1.7% for FOHGL [ES: -0.06, trivial effect]). Indeed, if repeated-measure analyses 299 are done without the Control group, the time x category interactions become statistically 300 significant both for the right and left hands (all p=0.02).

301

302

<insert Fig 2 here>

Fig 2. Pre- and post-statin withdrawal measures of physical performance

304	Data are expressed as mean \pm standard error; Post value with * is statistically different from
305	pre value with p \leq 0.01; Post value with † is statistically different from pre value with
306	p<0.05; ENEXT: endurance in extension (panel A); ENFLE: endurance in flexion (panel
307	B); FOEXT: force in extension (panel C); FOFLE: force in flexion (panel D); FOHGL:
308	hand grip force left (panel H); FOHGR: hand grip force right (panel G); POEXT: power in
309	extension (panel E); POFLE: power in flexion (panel F); SAMS: statin-associated muscle
310	symptoms.
311	

In order to establish whether observed changes in muscle functions are of clinical relevance, we codified as clinically significant any improvement greater or equal to 15% from baseline for any measure in a given individual (31). The number of patients from the two statin-using groups showing such improvements is reported in Table 2, and contingency analyses revealed that for five of the eight physical performance measures, the number of patients who experienced a clinical improvement in performance following statin weaning was statistically higher in the SAMS group.

- 319
- 320

Table 2. Proportion of patients who display clinically relevant performance

2	2	1
С	2	т

improvements following statin withdrawal

	SAMS No SAMS n / total (%) n / total (%)	Category p
ENEXT	23/54 (42.6) 2/13 (15.4)	0.05
ENFLE	28/54 (51.9) 4/13 (30.8)	0.17
FOEXT	9/54 (16.7) 1/13 (7.69)	0.38
FOFLE	13/54 (24.1) 2/13 (15.4)	0.49
POEXT	22/54 (40.7) 1/13 (7.69)	0.01
POFLE	29/54 (53.7) 3/13 (23.1)	0.04
FOHGR	6/32 (18.8) 0/12 (0.00)	0.04
FOHGL	7/25 (28.0) 0/12 (0.00)	0.01

322 Data are expressed as the number of patients with a 15% improvement in performance 323 following statin withdrawal / total number of patients in the considered group; p-values are shown here by a chi-squared test. SAMS: statin-associated muscle symptoms; For the other 324 325 abbreviations, see legends to Fig 2.

- 326
- 327 3.5. Targeting "real" sufferers of SAMS

328 For a subset (n=22) of SAMS-reporting patients, available data allowed us to assess the 329 likelihood of their symptoms being truly caused by statins using the SAMS-CI (16). Given very low numbers in the "unlikely" category, they were pooled with the "possible" 330 331 category for analyses. Subjective perception of symptoms resolution was greater in the 332 patients classified as "probable" for suffering from true SAMS using this classification 333 scheme (Fig 3). However, despite improvement in five of eight measures of physical 334 performance following statin withdrawal, we did not observe any significant difference 335 between categories or category x time interactions in repeated measures analyses (Fig 4). 336 337 <insert Fig 3 here> 338 Fig 3. Impact of statin withdrawal on perceived SAMS intensity by SAMS-CI category 339 using a visual analog scale from 0 to 10 340 Data are expressed as mean \pm standard error; Post value with * is statistically different from

341 pre value; SAMS: statin-associated muscle symptoms; SAMS-CI: SAMS - clinical index.

- 342
- 343

<insert Fig 4 here>

344 Fig 4. Impact of statin withdrawal on physical performance by SAMS-CI category

- 345 Data are expressed as mean \pm standard error; Post value with * is statistically different from
- 346 pre value with $p \le 0.01$; Post value with \dagger is statistically different from pre value with
- 347 p<0.05; SAMS-CI: statin-associated muscle symptoms clinical index; For the other
- abbreviations, see legends to Fig 2.

349 **4. Discussion**

350 In the face of frequent reports of SAMS (4-7), few objective data have shown negative 351 impacts of stating on muscle performance. Here we present evidence for modest but 352 relevant improvements on muscle function following statin withdrawal in patients self-353 reporting SAMS. Indeed, despite the lack of change in biochemical markers or clinical 354 indication of tissue damage, we observe for the entire cohort an overall improvement over 355 time following withdrawal in muscle functions for several objective measures of knee 356 extension and flexion (Fig 2). However, upon closer inspection, the greatest improvements 357 were observed in the SAMS group; in fact, within-group analyses showed no statistically 358 significant changes in the No SAMS and Control groups over time. Although the impact 359 of SAMS on performance remains debatable in the literature, our data aligned with those 360 of Parker et al. (2013) that showed differences in leg strength during isokinetic movements in extension at 60°/s and 180°/s and flexion at 60°/s between atorvastatin-treated 361 362 participants with or without muscle complaints (22). It is perhaps not surprising that we 363 observed an impairment in knee extension and flexion performances, as it has been shown 364 that SAMS tend to affect large muscle groups such as the quadriceps (17). Nevertheless, 365 and unlike that was reported by Parker et al. (2013) (22), we also observed significant though modest improvements in handgrip strength in the SAMS reporting group. 366

Using a cut-off value (15%) which can be considered clinically relevant and a value greater than what is expected from test habituation, we showed a clearly greater proportion of patients showing improvement in objective measures of muscle performance when reporting SAMS (Table 2). Though the average values of the improvements are modest, they are potentially important because they result in a decrease in the potential to perform

daily activities. Also, as muscle performance decreases with aging, the impact of such a
decrease in performance with statin use could be clinically more significant in this
population, which certainly merits further examination.

375 Our data must, of course, be nuanced in the context of a growing body of evidence for 376 a large nocebo effect in patients self-reporting SAMS (12-14, 32). For example, the work 377 of Howard et al. (2021) showed that most symptoms induced by statins were nocebo (32). 378 In the study, the investigators set up a 12-month multi-crossover trial in which 46 patients 379 in primary CV prevention and 14 patients in secondary CV prevention (65.5±8.6 yrs.) were 380 randomized in three conditions: statin, placebo, and no treatment. Every day, patients were 381 asked to rate the intensity of statin-associated symptoms (SAS). Results notably showed 382 differences in self-reported SAS intensity between the statin vs. no treatment and placebo 383 vs. no treatment conditions (p < 0.01), though no difference between the placebo and statin 384 conditions was observed (p=0.39). Though their work studied patients who reported SAS, 385 it did not specifically focus on SAMS. Whether or not our patients suffered of "true" SAMS 386 or a confounding nocebo effect, our data showing an objective impact of statin withdrawal 387 on self-reported symptoms intensity and objective measures is of important potential 388 clinical relevance. Indeed, recognizing that a patient could be suffering, objective impacts 389 on muscle functions could and should be considered in treatment assessment and follow 390 up.

It is of great importance to develop or validate tools that purport to identify likely sufferers of "true" SAMS (15). In this regard, a subset of our data allowed us to classify participants according to the SAMS-CI, a tool that has been proposed as potentially useful in a clinical setting but has yet to be validated (16). Using this approach, while we did

observe a greater improvement in subjective symptoms resolution in those classified as "probably" suffering from SAMS (Fig 3), we did not see any difference in objective measures between categories (Fig 4). These results should be interpreted with great caution as our analyses are weakened by a relatively low number of participants. Nevertheless, the demonstration of a greater subjective impact in the "probably" group does warrant further study on the potential usefulness of the SAMS-CI.

401 This study has several strengths. First, the lipid data indicate that we can be confident 402 about compliance with statin withdrawal. Second, the inclusion of a No SAMS group and 403 a Control group allows a more rigorous analysis and interpretation of results, even if these 404 groups are somewhat smaller. Third, the use of validated and standardized sensitive 405 objective measures allows us to discern little but real effects in muscle function. This study 406 is also, to our knowledge, the first work to attempt to validate the SAMS-CI. Finally, the 407 population recruited here represents a typical population of primary CV prevention patients 408 treated with stating, which reinforces the clinical relevance of our data.

409 A limitation of this study is that recruitment was based on self-reporting of SAMS. 410 Even if we limited the sources of bias using various recruitment criteria, we cannot be 411 certain of the potential influence of the nocebo effect on our results. On the other hand, 412 considering the growing interest in patient-reported outcomes in clinical studies and 413 especially their unique ability to be a true reflection of a "patient-centered approach" (33), 414 further insights into how individuals experience their SAMS and respond to quantitative 415 changes in objective clinical measures can enrich and clarify the evidence from quantitative 416 measures. This knowledge could be used in the future to develop intervention strategies 417 and lifestyle advice tailored to the individual needs of people receiving statin therapy.

418 Another potential cofounder is that the SAMS group was older and presented greater 419 markers of adiposity, which could have influenced some of the results. While the sample 420 studied in this report is typical of the patients' population at our lipid clinic, and thus 421 includes a variety of statins and doses, we cannot exclude differential impacts of these 422 varying formulations on our measures. Also, although all patients were sedentary and were 423 instructed not to change their physical activity habits during the protocol, this was not 424 objectively monitored, which may be a source of intra- and inter-patient variability. In 425 addition, the relatively small number of participants, particularly in the control and No 426 SAMS groups, and especially in the SAMS-CI sub-analysis, limits our statistical power 427 and could have masked the significance of some of the results. The small number of participants also did not allow for rigorous analyses by sex (although in the SAMS group, 428 429 baseline analyses did not indicate sex differences in response to drug withdrawal; data not 430 shown). Furthermore, all participants were Caucasian. While we also limited the 431 recruitment to patients between 30 and 60 yrs., primarily to avoid confounding effects of 432 conditions such as sarcopenia on muscle performance measures, this reduces the 433 generalizability of our findings. Our protocol is limited to a short follow-up of two months 434 with two visits (pre- and post-drug withdrawal). A longer follow-up could have led to 435 different conclusions. Finally, our protocol does not allow us to explore or discuss the 436 mechanisms of "true" SAMS.

437 **5.** Conclusions

438 Whether or not our study population suffered from "true" SAMS or nocebo effects, our 439 data indicate that participants who self-reported SAMS had improved physical function 440 concurrent with decreased subjective symptom intensity following drug withdrawal. 441 Although the negative impacts of statins on muscle function appear small, these could 442 nonetheless have real and substantive effects in certain patients or patient populations. For 443 example, in patients who have experienced sarcopenia or dynapenia, such as the frail 444 elderly or others suffering from various muscle diseases, an additional loss of even a small 445 portion of their functional capacity could contribute to important loss of independence and 446 health-related quality of life (HRQoL). Given the relative ease with which handgrip 447 strength can be measured, the present data certainly warrant future studies on its potential 448 clinical value in assessing functional changes with statin use in these populations.

449 Clearly, the present results need to be validated or recreated in other studies. More prospective data are needed, perhaps in the context of a randomized double-blinded study. 450 451 Furthermore, they need to be expanded to other statin populations, for example older 452 patients or those in secondary prevention. It also remains of great interest to further efforts 453 to better identify "true" SAMS sufferers and to assess whether functional impacts are 454 greater in this group. Finally, while we focus in this report on objective measures of muscle 455 functions, other impacts of self-reported SAMS such as those on HRQoL need further 456 study.

457 Acknowledgements

DRJ, JF and JB designed the study. NL provided clinical coordination, SSD, KG and CH participated in data collection, CH managed data validation and entry, PP, CH and DRJ performed statistical analyses. All participated in data interpretation. PP, under the direction of DRJ and PM, wrote the manuscript. All authors critically reviewed and accepted the final version of the article. The authors are grateful to patients for their participation.

464 References

- 465 1. Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al.
- 466 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA
- 467 Guideline on the Management of Blood Cholesterol: A Report of the American College of
- 468 Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
- 469 Circulation. 2019;139(25):e1082-e143.
- 470 2. Blaha MJ, Martin SS. How do statins work?: changing paradigms with implications
- 471 for statin allocation. J Am Coll Cardiol. 2013;62(25):2392-4.
- 472 3. Boulanger-Piette A, Bergeron J, Desgreniers J, Côté-Levesque M, Brassard D,
- 473 Joanisse DR, et al. [Statin intolerance and associated muscular dysfunctions]. Med Sci
- 474 (Paris). 2015;31(12):1109-14.
- 475 4. Thompson PD, Panza G, Zaleski A, Taylor B. Statin-Associated Side Effects. J Am
 476 Coll Cardiol. 2016;67(20):2395-410.
- 477 5. Bruckert E, Hayem G, Dejager S, Yau C, Begaud B. Mild to moderate muscular
- 478 symptoms with high-dosage statin therapy in hyperlipidemic patients--the PRIMO study.
- 479 Cardiovasc Drugs Ther. 2005;19(6):403-14.
- 6. Selva-O'Callaghan A, Alvarado-Cardenas M, Pinal-Fernandez I, Trallero-Araguas
 E, Milisenda JC, Martinez MA, et al. Statin-induced myalgia and myositis: an update on
 pathogenesis and clinical recommendations. Expert Rev Clin Immunol. 2018;14(3):21524.
- 484 7. Stroes ES, Thompson PD, Corsini A, Vladutiu GD, Raal FJ, Ray KK, et al. Statin485 associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society

486 Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J.
487 2015;36(17):1012-22.

- 8. Bouitbir J, Sanvee GM, Panajatovic MV, Singh F, Krahenbuhl S. Mechanisms of
- statin-associated skeletal muscle-associated symptoms. Pharmacol Res. 2020;154:104201.
- 490 9. Taylor BA, Thompson PD. Statin-Associated Muscle Disease: Advances in
- 491 Diagnosis and Management. Neurotherapeutics. 2018;15(4):1006-17.
- 492 10. Turner RM, Pirmohamed M. Statin-Related Myotoxicity: A Comprehensive
- 493 Review of Pharmacokinetic, Pharmacogenomic and Muscle Components. J Clin Med.
- 494 2019;9(1).
- Hauser W, Hansen E, Enck P. Nocebo phenomena in medicine: their relevance in
 everyday clinical practice. Dtsch Arztebl Int. 2012;109(26):459-65.
- 497 12. Blacher J, Bruckert E, Farnier M, Ferrieres J, Henry P, Krempf M, et al. [Myalgia
- and statins: Separating the true from the false]. Presse Med. 2019;48(10):1059-64.
- Pedro-Botet J, Climent E, Benaiges D. Muscle and statins from toxicity to the
 nocebo effect. Expert Opinion on Drug Safety. 2019;18(7):573-9.
- 501 14. Robinson JG. New insights into managing symptoms during statin therapy.
 502 Progress in Cardiovascular Diseases. 2019;62(5):390-4.
- 503 15. Alonso R, Cuevas A, Cafferata A. Diagnosis and Management of Statin
 504 Intolerance. J Atheroscler Thromb. 2019;26(3):207-15.
- 505 16. Rosenson RS, Miller K, Bayliss M, Sanchez RJ, Baccara-Dinet MT, Chibedi-De-
- 506 Roche D, et al. The Statin-Associated Muscle Symptom Clinical Index (SAMS-CI):
- 507 Revision for Clinical Use, Content Validation, and Inter-rater Reliability. Cardiovasc
- 508 Drugs Ther. 2017;31(2):179-86.

- 509 17. Berent T, Berent R, Steiner S, Sinzinger H. Statin-induced muscular side effects at
- rest and exercise An anatomical mapping. Atheroscler Suppl. 2019;40:73-8.
- 511 18. Ashfield TA, Syddall HE, Martin HJ, Dennison EM, Cooper C, Aihie Sayer A. Grip
- 512 strength and cardiovascular drug use in older people: findings from the Hertfordshire
- 513 Cohort Study. Age Ageing. 2010;39(2):185-91.
- 514 19. Krishnan GM, Thompson PD. The effects of statins on skeletal muscle strength and
 515 exercise performance. Curr Opin Lipidol. 2010;21(4):324-8.
- 516 20. Morville T, Dohlmann TL, Kuhlman AB, Sahl RE, Kriegbaum M, Larsen S, et al.
- 517 Aerobic Exercise Performance and Muscle Strength in Statin Users-The LIFESTAT Study.
- 518 Med Sci Sports Exerc. 2019;51(7):1429-37.
- 519 21. Noyes AM, Thompson PD. The effects of statins on exercise and physical activity.
 520 Journal of Clinical Lipidology. 2017;11(5):1134-44.
- 521 22. Parker BA, Capizzi JA, Grimaldi AS, Clarkson PM, Cole SM, Keadle J, et al. Effect
 522 of statins on skeletal muscle function. Circulation. 2013;127(1):96-103.
- 523 23. Williams PT, Thompson PD. Effects of Statin Therapy on Exercise Levels in
 524 Participants in the National Runners' and Walkers' Health Study. Mayo Clin Proc.
 525 2015;90(10):1338-47.
- 526 24. Kawai H, Ihara K, Kera T, Hirano H, Fujiwara Y, Tanaka M, et al. Association
 527 between statin use and physical function among community-dwelling older Japanese
 528 adults. Geriatr Gerontol Int. 2018;18(4):623-30.
- 529 25. Mallinson JE, Marimuthu K, Murton A, Selby A, Smith K, Constantin-Teodosiu D,

530 et al. Statin myalgia is not associated with reduced muscle strength, mass or protein

turnover in older male volunteers, but is allied with a slowing of time to peak power output,

insulin resistance and differential muscle mRNA expression. J Physiol. 2015;593(5):1239-533 57.

26. Panza GA, Taylor BA, Dada MR, Thompson PD. Changes in muscle strength in
individuals with statin-induced myopathy: A summary of 3 investigations. J Clin Lipidol.
2015;9(3):351-6.

537 27. Phillips PS, Haas RH, Bannykh S, Hathaway S, Gray NL, Kimura BJ, et al. Statin538 Associated Myopathy with Normal Creatine Kinase Levels. Annals of Internal Medicine.
539 2002;137(7):581–5.

540 28. Feiring DC, Ellenbecker TS, Derscheid GL. Test-Retest Reliability of the Biodex
541 lsokinetic Dynamometer. Journal of Orthopaedic & Sports Physical Therapy.

542 1990;11(7):298-300.

543 29. Mathiowetz V, Weber K, Volland G, Kashman N. Reliability and validity of grip
544 and pinch strength evaluations. The Journal of Hand Surgery. 1984;9(2):222-6.

545 30. Add-Ins J. Full Factorial Repeated Measures ANOVA Add-In 2014 [Available

546 from: <u>https://community.jmp.com/t5/JMP-Add-Ins/Full-Factorial-Repeated-Measures-</u>

547 <u>ANOVA-Add-In/ta-p/23904?trMode=source</u>.

548 31. Li RC, Wu Y, Maffulli N, Chan KM, Chan JL. Eccentric and concentric isokinetic
549 knee flexion and extension: a reliability study using the Cybex 6000 dynamometer. Br J
550 Sports Med. 1996;30(2):156-60.

551 32. Howard JP, Wood FA, Finegold JA, Nowbar AN, Thompson DM, Arnold AD, et

al. Side Effect Patterns in a Crossover Trial of Statin, Placebo, and No Treatment. J Am

553 Coll Cardiol. 2021;78(12):1210-22.

- 554 33. Cruz AC, Pedreira M. Patient-and Family-Centered Care and Patient Safety:
- reflections upon emerging proximity. Rev Bras Enferm. 2020;73(6):e20190672.

556

558 Supporting information

- 559 The study was supported by the Canadian Institutes of Health Research (CIHR grant MOP
- 560 114917 to DRJ, JB, and JF [https://cihr-irsc.gc.ca]). The funders had no role in study
- 561 design, data collection and analysis, decision to publish, or preparation of the manuscript.
- 562 The authors have declared that no competing interests exist.

564 List supporting information captions

- 565 S1 Table. Pre- and post-statin withdrawal plasma variables
- 566 SAMS: statin-associated muscle symptoms; FFA: free fatty acids; FBGL: fasting blood
- 567 glucose level; INS: insulin; TSH: thyroid-stimulating hormone; PTH: parathormone;
- 568 eGFR: estimated glomerular filtration rate; CRP: C-reactive protein; RF: rheumatoid
- 569 factor; Cr: creatinine; UR: urea; PA: pyruvic acid; LAC: lactic acid; LDH: lactate
- 570 dehydrogenase; ALKP: alkaline phosphatase; Ca: calcium; Na: sodium; K: potassium; Mg:
- 571 magnesium; NH4: ammonia; P: phosphorus; Cl: chloride; Data are expressed as mean ±
- SD ; Post value with * is statistically different from the pre value with $p \le 0.01$; Post value
- with \dagger is statistically different from the pre value with p<0.05.
- 574
- 575 S2 Table. Clinical profile of statin users
- 576 SAMS: statin-associated muscle symptoms; * Framingham Score: values are means \pm SD and
- 577 ANOVA p=0.06.







